1. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer. Issue 1 (2nd January 2023) Authors: Yang, James Chih-Hsin; Zhou, Caicun; Jänne, Pasi A.; Ramalingam, Suresh S.; Kim, Tae Min; Riely, Gregory J; Spira, Alexander I; Piotrowska, Zofia; Mekhail, Tarek; Garcia Campelo, Maria Rosario; Felip, Enriqueta; Bazhenova, Lyudmila; Jin, Shu; Kaur, Manmit; Diderichsen, Paul M.; Gupta, Neeraj; Bun... Journal: Expert review of anticancer therapy Issue: Volume 23:Issue 1(2023) Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Issue 5 (13th March 2019) Authors: Leaf, Rebecca Karp; Ferreri, Christopher; Rangachari, Deepa; Mier, James; Witteles, Wesley; Ansstas, George; Anagnostou, Theodora; Zubiri, Leyre; Piotrowska, Zofia; Oo, Thein H.; Iberri, David; Yarchoan, Mark; Salama, April K. S.; Johnson, Douglas B.; Leavitt, Andrew D.; Rahma, Osama E.; Reynolds... Journal: American journal of hematology Issue: Volume 94:Issue 5(2019:May) Page Start: 563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. (December 2022) Authors: Lee, Jiyun; Piotrowska, Zofia; Soo, Ross; Cho, Byoung Chul; Lim, Sun Min Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?. (23rd October 2015) Authors: Piotrowska, Zofia; Sequist, Lecia V. Journal: Oncologist Issue: Volume 20:Number 11(2015) Page Start: 1230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Epidermal Growth Factor Receptor–Mutant Lung Cancer. Issue 5 (September 2015) Authors: Piotrowska, Zofia; Sequist, Lecia V. Journal: Cancer journal Issue: Volume 21:Issue 5(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 study. (March 2022) Authors: Popat, Sanjay; Ramalingam, Suresh; Kim, Tae Min; Yang, James; Riely, Gregory; Mekhail, Tarek; Nguyen, Danny; Garcia Campelo, Maria Rosario; Felip, Enriqueta; Spira, Alexander; Piotrowska, Zofia; Bazhenova, Lyudmila; Vincent, Sylvie; Jin, Shu; Griffin, Celina; Diderichsen, Paul; Gupta, Neeraj; Bun... Journal: Lung cancer Issue: Volume 165(2022)Supplement 1 Page Start: S30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy. Issue 11 (November 2015) Authors: Al-Halabi, Hani; Sayegh, Karl; Digamurthy, Subba R.; Niemierko, Andrzej; Piotrowska, Zofia; Willers, Henning; Sequist, Lecia V. Journal: Journal of thoracic oncology Issue: Volume 10:Issue 11(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Plasma T790M Result Alters Treatment Options in a Previously T790 Wild‐TypeEGFR‐Mutant Lung Cancer. Issue 8 (August 2016) Authors: Piotrowska, Zofia; Drapkin, Benjamin; Engelman, Jeffrey A.; Nagy, Rebecca J.; Lanman, Richard B.; Sequist, Lecia V. Journal: Journal of thoracic oncology Issue: Volume 11:Issue 8(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer. (2021) Authors: Neal, Joel W.; Costa, Daniel B.; Muzikansky, Alona; Shrager, Joseph B.; Lanuti, Michael; Huang, James; Ramachandran, Kavitha J.; Rangachari, Deepa; Huberman, Mark S.; Piotrowska, Zofia; Kris, Mark G.; Azzoli, Christopher G.; Sequist, Lecia V.; Chaft, Jamie E. Journal: JCO precision oncology Issue: Volume 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I‐IIIEGFR‐Mutant Non‐Small‐Cell Lung Cancer. (December 2021) Authors: Neal, Joel W.; Costa, Daniel B.; Muzikansky, Alona; Shrager, Joseph B.; Lanuti, Michael; Huang, James; Ramachandran, Kavitha J.; Rangachari, Deepa; Huberman, Mark S.; Piotrowska, Zofia; Kris, Mark G.; Azzoli, Christopher G.; Sequist, Lecia V.; Chaft, Jamie E. Journal: JCO precision oncology Issue: Volume 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗